{"id":614313,"date":"2022-09-01T09:32:41","date_gmt":"2022-08-31T19:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=614313"},"modified":"2022-08-31T19:30:01","modified_gmt":"2022-08-31T19:30:01","slug":"hereditary-angioedema-market-to-exhibit-substantial-growth-by-2032-estimates-delveinsight-key-companies-csl-behring-takeda-shire-pharming-group-biocryst-ionis-kalvista-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hereditary-angioedema-market-to-exhibit-substantial-growth-by-2032-estimates-delveinsight-key-companies-csl-behring-takeda-shire-pharming-group-biocryst-ionis-kalvista-and-others_614313.html","title":{"rendered":"Hereditary Angioedema Market to Exhibit Substantial Growth by 2032 – Estimates DelveInsight | Key Companies – CSL Behring, Takeda, Shire, Pharming Group, BioCryst, Ionis, KalVista, and Others"},"content":{"rendered":"
\n
\"Hereditary<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Hereditary Angioedema Market size was found to be USD 1,987 million in 2020 in the 7MM, which is expected to increase during the forecast period (2019-32). As per the DelveInsight, the current understanding of Hereditary Angioedema has greatly improved in recent decades, leading to growing awareness, improved management, and better outcomes.<\/div>\n

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032″<\/strong> report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Angioedema Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Hereditary Angioedema market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Hereditary<\/p>\n

Hereditary Angioedema: An Overview<\/strong><\/p>\n

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx<\/p>\n

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.<\/em><\/p>\n

Hereditary Angioedema Market Key Facts<\/strong><\/p>\n